10 Clinical Posters Featuring MolecuLight Highlight its Progress Towards Becoming the Standard of Care

MolecuLight's showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care. MolecuLight's showing at...
Comunicato Precedente

next
Comunicato Successivo

next
TORONTO, (informazione.it - comunicati stampa - salute e benessere)

MolecuLight's showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care.

"We are thrilled to see such a strong representation of MolecuLight research at SAWC Fall, which demonstrates the ever-growing adoption and support of our device. The 10 clinical posters being presented highlight the continuously expanding body of evidence in support of the implementation of our technology as part of the standard of care for wound infection management as this has proven to enhance patient outcomes," says Anil Amlani, CEO of MolecuLight, Inc. "MolecuLight is a unique technology in the field, with integrated multiple functions that provide clinicians with a global overview of the wounds' evolution, documents their interventions and findings and enriches every patent encounter with highly accurate, point-of-care information about bacterial burden and wound size."

The clinical posters featuring the MolecuLight at SAWC Fall 2024 are as follows:

About MolecuLight

The MolecuLight i:X® and DX™ are the only Class II FDA cleared imaging devices for real-time detection of elevated levels of bacteria in wounds, surgical sites, and other injuries. With unmatched clinical evidence including 100+ peer-reviewed publications representing over 3500 patients, their innovative devices empower healthcare providers to target bacterial removal and make informed treatment decisions. By detecting bacteria in its early stages, MolecuLight technology improves infection management for exceptional patient outcomes.

10 Clinical Posters Featuring MolecuLight Highlight its Progress Towards Becoming the Standard of Care

The multi-modal MolecuLight devices combine bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow.

www.moleculight.com

For more information, contact: Hunter Zudans, Director of Marketing, Moleculight Inc., T. 416.542.5507, [email protected]

Cision View original content:https://www.prnewswire.co.uk/news-releases/10-clinical-posters-featuring-moleculight-highlight-its-progress-towards-becoming-the-standard-of-care-302264962.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili